Syndax Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Syndax Pharmaceuticals şirketinin toplam hissedar öz sermayesi $366.4M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $425.8M ve $59.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$406.40m
Eşitlik	US$366.43m
Toplam yükümlülükler	US$59.38m
Toplam varlıklar	US$425.81m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 1T3 'nin kısa vadeli varlıkları ( $414.8M ) kısa vadeli yükümlülüklerini ( $59.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: 1T3 şirketinin kısa vadeli varlıkları ( $414.8M ) uzun vadeli yükümlülüklerini ( $2.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 1T3 borçsuzdur.

Borcun Azaltılması: 1T3 un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 1T3 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 1T3 serbest nakit akışı her yıl % 26.2 1.8 yıl yetecek nakit akışına sahip olacaktır.

Syndax Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Syndax Pharmaceuticals Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

New minor risk - Share price stability

Syndax Pharmaceuticals, Inc. Announces Positive Pivotal Topline Results from Relapsed or Refractory Mnpm1 AML Cohort in Augment-101 Trial of Revumenib

Syndax Pharmaceuticals, Inc. Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™? (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting

Syndax Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

New minor risk - Share price stability

Syndax Announces Pdufa Action Date Extension for Revumenib Nda for Relapsed or Refractory Kmt2ar Acute Leukemia

Syndax Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Index

SSyndax Pharmaceuticals, Inc. Presents Updated Positive Data from BEAT AML and Augment-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress

Syndax Pharmaceuticals Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC

Syndax Pharmaceuticals, Inc. Announces Board Changes

Syndax Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024

Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Pharmaceuticals, Inc. Announces Executive Changes

New minor risk - Profitability

Syndax Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Now 24% undervalued

Syndax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999985 million.

Syndax Pharmaceuticals Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Syndax Pharmaceuticals Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting

Syndax Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Syndax Pharmaceuticals Announces to Initiate Nda Submission of Revumenib in Relapsed/Refractory Kmt2ar Acute Leukemia Under Fda's Real-Time Oncology Review Program

New minor risk - Share price stability

Syndax Pharmaceuticals Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stated Interim Analysis

Syndax Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

Insufficient new directors

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.40 loss in 3Q 2021)

Syndax Pharmaceuticals, Inc. Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of Augment-101 Trial of Revumenib in Patients with Acute Leukemias

Syndax Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

First half 2022 earnings released

Syndax Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Insufficient new directors

Investor sentiment improved over the past week

Syndax Pharmaceuticals, Inc. Announces Appointment of Keith A. Goldan as Chief Financial Officer

Investor sentiment improved over the past week

First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.54 loss in 1Q 2021)

Syndax Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 09, 2022

Investor sentiment improved over the past week

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals, Inc. Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613

Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease

Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.46 loss in 3Q 2020)

Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million.

First half 2021 earnings released: US$0.98 loss per share (vs US$0.97 loss in 1H 2020)

First quarter 2021 earnings released: US$0.54 loss per share (vs US$0.56 loss in 1Q 2020)

Independent Chairman recently bought €164k worth of stock

Full year 2020 earnings released: US$1.87 loss per share (vs US$1.84 loss in FY 2019)

Revenue beats expectations

Syndax Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 08, 2021

Syndax Pharmaceuticals, Inc. Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD

New 90-day high: €19.50

Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting

New 90-day high: €16.00

Third quarter 2020 earnings released: US$0.46 loss per share

Revenue misses expectations

Syndax Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 02, 2020

New 90-day high: €15.30

New 90-day high: €14.50

First half earnings released